Jolie Siegel - 10 Sep 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Legal Officer
Signature
/s/ Shoaib Ghias, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
10 Sep 2021
Net transactions value
-$562,750
Form type
4
Filing time
14 Sep 2021, 16:08:34 UTC
Previous filing
02 Aug 2021
Next filing
16 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $62,250 +12,500 $4.98 12,500 10 Sep 2021 Direct
transaction CCCC Common Stock Sale $625,000 -12,500 -100% $50.00* 0 10 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -12,500 -4.4% $0.000000 271,321 10 Sep 2021 Common Stock 12,500 $4.98 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
F2 20% of this option vested and became exercisable on July 1, 2021, with the remainder vesting in 16 equal quarterly installments thereafter.